AOD-9604 for Weight Loss
AOD-9604 is a modified fragment of human growth hormone (hGH176-191) that retains the fat-burning properties of hGH without the blood sugar, IGF-1, or growth-promoting effects. It directly stimulates lipolysis in adipose tissue — making it uniquely suited for targeting stubborn fat deposits and body recomposition rather than large-scale weight reduction.
How AOD-9604 Burns Fat Without Side Effects
AOD-9604 binds beta-3 adrenergic receptors in adipose tissue, directly triggering the breakdown of stored triglycerides into free fatty acids. This is the same lipolytic pathway activated by catecholamines during exercise — AOD-9604 essentially mimics the fat-burning signal without requiring the cardiovascular stress of exercise.
Beyond stimulating fat breakdown, AOD-9604 inhibits lipogenesis — the conversion of carbohydrates and other substrates into new fat. This dual action (more lipolysis + less lipogenesis) produces a net reduction in adipose tissue mass over time, particularly in stubborn fat deposits that are resistant to diet and exercise alone.
Full hGH stimulates IGF-1 production, which drives cell proliferation and can promote cancer growth in susceptible individuals. AOD-9604 lacks the IGF-1-stimulating domain of hGH — it retains only the lipolytic fragment (amino acids 176–191). This makes it significantly safer than hGH for long-term use as a fat loss agent.
Unlike GLP-1 agonists, AOD-9604 has no effect on appetite, insulin secretion, or blood glucose. It works purely at the adipose tissue level. This makes it complementary to GLP-1 agonists (which work through appetite suppression) and ideal for users who want targeted fat loss without systemic metabolic effects.
AOD-9604 Weight Loss Dosage Protocols
| Protocol | Daily Dose | Timing | Duration | Notes |
|---|---|---|---|---|
| Conservative | 250mcg/day | Morning fasted | 12 weeks | METAOD-001 low-dose arm; well tolerated |
| Standard | 500mcg/day | 250mcg AM fasted + 250mcg pre-sleep | 12–24 weeks | Most common protocol; best clinical evidence |
| Advanced | 500–1000mcg/day | Split 2–3x daily, fasted | 12–16 weeks | Higher doses not well-studied; diminishing returns above 500mcg |
Injection technique: Subcutaneous injection into abdominal fat (preferred), thigh, or upper arm. Rotate sites. Use insulin syringe (29–31G, 0.5–1mL). Reconstitute with bacteriostatic water; store at 2–8°C after reconstitution.
AOD-9604 vs GLP-1 Agonists for Weight Loss
| Factor | AOD-9604 | Semaglutide | Tirzepatide |
|---|---|---|---|
| Mechanism | Beta-3 adrenergic receptor activation → lipolysis | GLP-1 receptor → appetite suppression | GIP + GLP-1 → appetite + metabolism |
| Weight loss magnitude | Modest (2–5% body weight) | Large (15–17% body weight) | Large (20–22% body weight) |
| Appetite suppression | None | Strong | Very strong |
| Targets stubborn fat | Yes (direct lipolysis) | Indirect (caloric deficit) | Indirect (caloric deficit) |
| Blood sugar impact | None | Lowers blood glucose | Lowers blood glucose |
| Muscle preservation | Good (no catabolic effect) | Moderate concern | Moderate concern |
| Best for | Body recomposition, stubborn fat | Large-scale weight loss | Large-scale weight loss + T2D |
AOD-9604 Stacking Strategies for Weight Loss
The most powerful fat loss stack: GLP-1 agonist (Semaglutide or Tirzepatide) handles appetite suppression and caloric restriction; AOD-9604 directly targets adipose tissue lipolysis. The two mechanisms are complementary and non-overlapping. This stack is used by advanced users seeking maximum fat loss with body recomposition.
CJC-1295/Ipamorelin elevates GH → IGF-1, promoting lean mass accretion and fat loss. AOD-9604 adds direct lipolytic action. Together they produce body recomposition: fat loss + lean mass gain simultaneously. Best for users who want to improve body composition without significant total weight change.
As fat is lost, skin laxity becomes a concern — particularly for users losing significant body fat. GHK-Cu stimulates collagen synthesis and skin elasticity. Stacking AOD-9604 + GHK-Cu addresses both the fat loss goal and the skin quality concern simultaneously.
For users new to peptides or wanting to isolate AOD-9604's effects, a solo protocol at 500mcg/day for 12 weeks is a clean starting point. Minimal side effects, no hormonal impact, and provides a clear baseline for assessing response before adding additional compounds.
AOD-9604 from Purgo Labs
≥99% purity, third-party COA verified, cGMP facility.
Use code HEALTH for 15% off.
Shop AOD-9604Frequently Asked Questions
What is the best AOD-9604 dosage for weight loss?
The most studied AOD-9604 dosage for weight loss is 250–500mcg per day, administered subcutaneously. The original clinical trials used 250mcg/day and 500mcg/day doses. The 500mcg/day dose produced the most consistent fat loss results in the METAOD-001 trial. Most protocols split the dose into two injections (morning fasted + pre-sleep) to maintain steady plasma levels.
How long does AOD-9604 take to work for weight loss?
Most users report noticeable changes in body composition within 6–12 weeks of consistent use. The METAOD-001 Phase 2b trial showed statistically significant weight loss at 12 weeks compared to placebo. The mechanism — stimulating fat cell lipolysis and inhibiting lipogenesis — is gradual and cumulative. Combining AOD-9604 with a caloric deficit and resistance training accelerates results.
How does AOD-9604 cause weight loss without affecting blood sugar?
AOD-9604 is a modified fragment of human growth hormone (hGH176-191) that retains the lipolytic (fat-burning) region of the hGH molecule but lacks the IGF-1-stimulating domain. This means it activates beta-3 adrenergic receptors in adipose tissue to stimulate fat breakdown without the insulin resistance, glucose elevation, or IGF-1-driven cell proliferation associated with full hGH. It's metabolically clean — no impact on blood glucose or insulin sensitivity at therapeutic doses.
Should AOD-9604 be injected fasted for weight loss?
Yes — morning fasted injection is the standard protocol for maximizing lipolytic effect. Insulin blunts the fat-mobilizing action of AOD-9604, so injecting in a fasted state (before breakfast, after overnight fast) ensures maximum receptor availability. If splitting into two daily doses, the second injection is typically pre-sleep (4–6 hours after last meal) for the same reason.
Can AOD-9604 be stacked with other peptides for weight loss?
Yes — common stacks include: (1) AOD-9604 + CJC-1295/Ipamorelin for body recomposition (fat loss + lean mass); (2) AOD-9604 + GHK-Cu for skin tightening alongside fat loss; (3) AOD-9604 + BPC-157 for recovery support during caloric deficit. AOD-9604 is also frequently stacked with GLP-1 agonists (Semaglutide/Tirzepatide) as a complementary mechanism — GLP-1s reduce appetite/caloric intake while AOD-9604 directly targets adipose tissue lipolysis.
Is AOD-9604 better than GLP-1 peptides for weight loss?
AOD-9604 and GLP-1 agonists work through completely different mechanisms and are not directly comparable. GLP-1 agonists (Semaglutide, Tirzepatide) produce significantly greater total weight loss (15–22% body weight) primarily through appetite suppression and caloric restriction. AOD-9604 produces more modest total weight loss but works directly on adipose tissue lipolysis — making it more useful for targeting stubborn fat deposits and body recomposition rather than large-scale weight reduction. Many advanced users stack both.